Report Scope
This report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.

Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions?North America, Europe and Asia-Pacific?and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.

The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.

For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.

Report Includes

  • 55 data tables and 70 additional tables
  • An updated overview and in-depth analysis of the global influenza market
  • Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
  • Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
  • Analysis of the market opportunities through the Porter’s Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
  • Insight into the influenza industry structure, government regulations, and key development issues
  • Analysis of the key patent grants and IP aspects
  • A discussion of the industry’s ESG challenges and practices of the industry
  • Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
  • Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott